Analysts appeared unfazed by the news that a patient treated with Cabaletta Bio’s autoimmune CAR-T suffered a toxicity complication during a phase 1/2 trial. Cabaletta has been evaluating the CAR-T, ...

Cabaletta Bio’s shares tumbled 13% Friday morning as the biotech shared just a crumb of data from two patients in an autoimmune CAR-T trial that hinted at remission. The data came from the first two ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PHILADELPHIA, PA - Cabaletta Bio (NASDAQ:CABA), Inc., a biotechnology firm specializing in biological products, announced today that it has entered into a material definitive agreement amending its ...

Cabaletta Bio, Inc. announced promising clinical data regarding its investigational therapy, resecabtagene autoleucel (rese-cel), for autoimmune diseases during recent scientific meetings. Among the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining ...

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 ...

– RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly ...

Cabaletta Bio (NASDAQ:CABA) announced on Wednesday the pricing of an underwritten public offering consisting of 39.2 million shares of its common stock and accompanying warrants to purchase an ...